“…Other less commonly used systemic steroid‐sparing agents include mycophenolate mofetil, methotrexate, colchicine, azathioprine, sulfasalazine, 6‐mercaptopurine, and tacrolimus. If an underlying inflammatory bowel disease is identified, TNF‐α inhibitors, such as infliximab (5 mg/kg per dose) or adalimumab (40 mg every other week) were of choice for controlling both conditions . We shouldn't forget wound care as an important part in the optimal environment for wound healing …”